# Spatial transcriptome of a germinal center plasmablastic burst hints at *MYD88/CD79B* mutants-enriched diffuse large B-cell lymphomas

Vincenzo L'Imperio<sup>1\*</sup>, Gaia Morello<sup>2\*</sup>, Maria Carmela Vegliante<sup>3</sup>, Valeria Cancila<sup>2</sup>, Giorgio Bertolazzi<sup>2</sup>, Saveria Mazzara<sup>4</sup>, Beatrice Belmonte<sup>2</sup>, Alessandro Mangogna<sup>5</sup>, Piera Balzarini<sup>6</sup>, Lilia Corral<sup>7</sup>, Gianluca Lopez<sup>8</sup>, Arianna Di Napoli<sup>8</sup>, Fabio Facchetti<sup>9</sup>, Fabio Pagni<sup>1#</sup>, Claudio Tripodo<sup>2,10#</sup>

#### **Supplementary Materials**

**Supplemental Table S1.** List of the 54 genes recurrently mutated in lymphomas included in the targeted NGS panel.

**Supplemental Table S2.** Targeted NGS of 54 genes recurrently mutated in lymphomas performed on the microdissected GEx GC.

**Supplemental Table S3.** Expression of 1824 genes over 24 ROIs obtained through GeoMx Digital Spatial Profiler of NanoString. NanoString has performed the Q3 normalization.

**Supplemental Table S4.** Differentially expressed genes among DZ, LZ, PERI and GEx ROI types (Kruskal-Wallis adjusted p-values < 0.05) and relative gene set enrichment analysis (KEGG, Reactome Pathway, and GO-BP libraries).

**Supplemental Table S5.** Average SpatialDecon cell fraction estimations over 24 DZ, LZ, PERI and GEx ROIs. Kruskal-Wallis test has been used to compare cell fraction distributions among ROIs.

**Supplemental Table S6.** Fisher exact test p-values from enrichment analysis on cluster 1 and cluster 2 among cell of origin categories in DLBCL cases relative to the Schmitz *et al.* dataset (6).

**Supplemental Table S7.** Fisher exact test p-values from enrichment analysis on cluster 1 and cluster 2 among genetic subtype categories in DLBCL cases relative to the Schmitz *et al.* dataset (6).

**Supplemental Table S8.** Pairwise comparisons of average GEx signature scores over genetic subtype categories in DLBCL cases relative to the Schmitz *et al.* (6) and Chapuy *et al.* (5) datasets through Bootstrap t-test.

**Supplemental Table S9.** Average CIBERSORTx cell fraction estimations over cluster 1 and cluster 2 DLBCL cases relative to the Schmitz *et al.* dataset (6). Wilcoxon-Mann-Whitney test has been used to compare cell fraction distributions among clusters.

#### **Supplementary Data**

**Supplementary Figure S1.** Immunostaining for HHV8 (Original magnifications x50, inset x200) (**A**) and EBER in situ hybridization (Original magnifications x50, inset x200) (**B**) were negative in the described germinotropic expansion of the tonsil (asterisk).

**Supplementary Figure S2. A-B,** PCR-based gene scan clonality analysis with master mixes targeting the framework 1, 2, 3 (FR) and the joining region (J) (A) or the diversity (D) regions

with the joining region (J) (**B**) of the IGH locus showed a polyclonal rearrangement of the IGH gene in both the sample and the polyclonal control, whereas a clonal peak (arrow) was present in the monoclonal control. **C**, Similarly, the sample showed a polyclonal rearrangement in both the multiplex PCR targeting the variable (V) and the joining (J) regions or the deleting element (Kde) with the variable (V) or intragenic J $\varkappa$ -C $\varkappa$  regions of the IGK chain locusH.

**Supplementary Figure S3.** Fluorescent in situ hybridization using an IRF4/DUSP22 break apart probe indicates the absence of gene rearrangements (two red and green fusion-signals in the majority of the cells).

**Supplementary Figure S4.** Heatmap of the average gene expression of 10 marker genes selected according to Figure 1B immunophenotypical analyses of the DZ, LZ, Peri, and GEx ROIs.

**Supplementary Figure S5. A**, Comparative analysis of CD138, IRF4 and CD3 IHC markers in 24 ROIs in the profiled GEx, DZ, LZ and Peri regions. **B**, Heatmap of the expression of the quantitative immunohistochemical analysis of CD3, CD138, and IRF4 markers evaluated in the DZ, LZ, PERI, and GEx regions. The bootstrap t-test has been used to compare GEx ROIs with others.

**Supplementary Figure S6. A,** Cumulative distributions of the 17 genes GEx signature expression per patient among the two groups (Kolmogorov-Smirnov p-value < 10e-16). **B**, Overall survival of the two groups of BLBCL cases obtained from the unsupervised clustering of the Schmitz *et al.* dataset (6). **C**, Progression free survival of the two clusters obtained from the unsupervised clustering. **D-E**, GEx score distribution over genetic subtypes categories in

Schmitz *et al.* (6) (D) and Chapuy *et al.* (5) (E) datasets. The GEx score has been calculated as the difference between the sum of GEx-UP gene expression and the sum of GEx-DOWN gene expression. The bootstrap t-test has been used to compare the average values (rhomboid points) among the genetic subtypes categories.



#### Α







С



#### В

## IRF4/DUSP22







Α



В





Genetic subtypes

Other, ABC

Other.GCB

Other.UC

120

100<sup>-</sup> 80<sup>-</sup>

BNZ

£18

NCD

Genetic subtypes

ථ

్రీ

د∿

с<sup>р</sup>

120

100-

80

ŝ

ŝ